Advertisement
Advertisement
ALDX
Aldeyra Therapeutics, Inc.
0.63
USDSponsored
-0.01
-1.08%
Nov 10, 15:59 UTC -5
Closed
After-Market
0.62
-0.01
-1.29%
Aldeyra Therapeutics, Inc. (ALDX) Earnings
ALDX Earnings Reports
Positive Surprise Ratio
ALDX beat 28 of 44 last estimates.
64%
Next Report
Date of Next Report
Feb 25, 2027
Estimate for Q4 26 (Revenue/ EPS)
--
/-$0.10
Implied change from Q3 26 (Revenue/ EPS)
--
/+66.67%
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Aldeyra Therapeutics, Inc. earnings per share and revenue
On Nov 05, 2026, ALDX reported earnings of -0.06 USD per share (EPS) for Q3 26, beating the estimate of -0.09 USD, resulting in a 37.43% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +2.89% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.10 USD, with revenue projected to reach -- USD, implying an increase of 66.67% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Definium Therapeutics, Inc. Common Shares
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$0.56
Actual
-$0.46
Surprise
+19.06%
Ocular Therapeutix, Inc.
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$0.36
Actual
-$0.42
Surprise
-13.54%
Harrow, Inc. Common Stock
Report Date
Nov 09, 2026 For Q3 26
Estimate
$0.22
Actual
$0.12
Surprise
-45.92%
SIGA Technologies Inc.
Report Date
Nov 09, 2026 For Q3 26
Estimate
-Actual
-$0.04
Surprise
-
Protara Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.35
Surprise
+6.17%
Minerva Neurosciences, Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.12
Actual
$1.94
Surprise
+1,629.97%
Tonix Pharmaceuticals Holding Corp.
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$2.40
Actual
-$2.89
Surprise
-20.23%
Cumberland Pharmaceuticals Inc
Report Date
Nov 10, 2026 For Q3 26
Estimate
-Actual
-$0.07
Surprise
-
PMV Pharmaceuticals, Inc
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
Corbus Pharmaceuticals Holdings, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$1.23
Actual
-$1.81
Surprise
-46.07%
FAQ
What were Aldeyra Therapeutics, Inc.'s earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Aldeyra Therapeutics, Inc. reported EPS of -$0.06, beating estimates by 37.43%, and revenue of $0.00, 0% as expectations.
How did the market react to Aldeyra Therapeutics, Inc.'s Q3 2026 earnings?
The stock price moved up 2.89%, changed from $0.62 before the earnings release to $0.63 the day after.
When is Aldeyra Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Feb 25, 2027.
What are the forecasts for Aldeyra Therapeutics, Inc.'s next earnings report?
Based on --
analysts, Aldeyra Therapeutics, Inc. is expected to report EPS of -$0.10 and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.